Monitor the company's upcoming 10-Q for any guidance or financial updates, as this proxy filing contains no new financial information. The vote on executive compensation could be a minor read-through for investor sentiment if there is a significant 'say on pay' dissent, but none is indicated here.
EWTX drugs
EWTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 24 $31.58entry
- T+1 · 7mo ago −2.98%α −3.14% · $30.64
- T+5 · 7mo ago −1.96%α −2.87% · $30.96
- T+20 · 6mo ago +3.51%α −0.51% · $32.69
- T+60 · 4mo ago +25.33%α +20.25% · $39.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Edgewise Therapeutics is holding its 2026 Annual Meeting where shareholders are asked to vote on three proposals: electing three director nominees, ratifying KPMG LLP as the independent auditor, and approving the compensation of named executive officers. The filing is a definitive proxy statement filed by the company, indicating standard, routine corporate governance matters.
Key Financial Metrics
Key Facts
- The filing is a DEFA14A, a definitive proxy statement for the 2026 Annual Meeting.
- Three proposals are on the ballot: election of directors (Laura Brege, Badreddin Edris, Jonathan Root), ratification of KPMG LLP as auditors, and an advisory vote on executive compensation.
- The company is requesting votes by June 3, 2026, for a meeting on June 4, 2026.
- The filing was made by the registrant (Edgewise Therapeutics, Inc.), not a dissident party.
Financial Impact
No immediate financial impact. This is a routine governance filing.
Risk Factors
- Low. The primary risk is a potential 'say on pay' vote failure, which could signal governance concerns, but this is not indicated in the current filing.
- The routine nature of the proposals means there is minimal risk to the company's operations or stock price from this event.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-047691 |
| Document: 0001104659-26-047691-index-headers.html | 0001104659-26-047691 |
| Document: 0001104659-26-047691-index.html | 0001104659-26-047691 |
| Document: 0001104659-26-047691.txt | 0001104659-26-047691 |
Track record
14 reports on EWTX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 144 Neutral 1/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
- Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
- Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers